A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
|Articles|August 18, 2006
Opinion for benchmarking basic skills of laparoscopic surgery for residents Video
From the 34th Annual Meeting - Chicago, Illinois - November 2005
Advertisement
The file you requested will begin playing automatically. If it does not, press the 'play' button. If you experience playback problems, make certain you have the latest version of Windows Media Player, available
Advertisement
Related to this article
Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
3
Chrisandra Shufelt, MD, on cardiovascular prevention at menopause
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5